Lamivudine 150 mg
Lamivudine 150 mg Tablets are a nucleoside reverse transcriptase inhibitor used as a key component of combination antiretroviral therapy, supporting sustained viral suppression in patients with HIV-1 infection in line with recommended clinical guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
150 mg twice daily or 300 mg once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets
Lamivudine 150 mg
Lamivudine 150 mg Tablets are a nucleoside reverse transcriptase inhibitor used as a key component of combination antiretroviral therapy, supporting sustained viral suppression in patients with HIV-1 infection in line with recommended clinical guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
150 mg twice daily or 300 mg once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets
Lamivudine 150 mg
Lamivudine 150 mg Tablets are a nucleoside reverse transcriptase inhibitor used as a key component of combination antiretroviral therapy, supporting sustained viral suppression in patients with HIV-1 infection in line with recommended clinical guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
150 mg twice daily or 300 mg once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets